drugset / Trial / NCT00117234

Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia

NCT00117234

Completed Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to evaluate the effect of treatment with darbepoetin alfa on peak oxygen consumption (peak VO2) in subjects with symptomatic CHF and anemia.

Timeline

Start
2002-09
Primary completion
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic 0.75 ug/kg Subcutaneous